Medical/Pharmaceuticals

Lasermach by Wingderm® Receives FDA Clearance for All Three Wavelengths

BEIJING, March 26, 2026 /PRNewswire/ -- Wingderm®, a manufacturer of medical aesthetic devices, announces that its Lasermach system has received expanded clearance from the U.S. Food and Drug Administration (FDA). With this latest clearance, Lasermach now achieves FDA clearance across all three w...

2026-03-26 18:00 3010

HEALTH SUMMIT ASIA 2026 CONFIRMS OVER 30 GLOBAL HEALTHCARE LEADERS FOR CONFERENCE

KUALA LUMPUR, Malaysia, March 26, 2026 /PRNewswire/ -- Health Summit Asia (HSA) 2026 has confirmed more than 30 distinguished speakers from across the globe, underscoring the event's scale and significance for Malaysia and the wider region. Their calibre spans public health, cancer research, AI i...

2026-03-26 14:30 4256

GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala

- First regulatory clearance in Latin America marks a strategic milestone for regional market expansion - World's first antibiotic-free manufacturing process ensures superior safety profile YONGIN, South Korea, March 26, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biophar...

2026-03-26 14:23 3843

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...

2026-03-26 13:13 7056

Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction

TOKYO, March 26, 2026 /PRNewswire/ -- NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of S...

2026-03-26 10:00 5111

Hengrui Pharma Announces Strong 2025 Annual Results

SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attribut...

2026-03-26 08:52 4463

XtalPi Holdings Announces Full Year 2025 Annual Results

HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. * Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making th...

2026-03-25 22:27 8138

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...

2026-03-25 21:01 5361

Heidi Receives Frost & Sullivan's 2026 North American Technology Innovation Leadership Recognition for Excellence in Artificial Intelligence Medical Scribe Innovation

The recognition highlights Heidi's leadership in clinical AI innovation, market impact, and customer-centric technology design. SAN ANTONIO, March 25, 2026 /PRNewswire/ -- Frost & Sullivan

2026-03-25 21:00 3639

Axtria Recognized as Frost & Sullivan's 2025 Global Company of the Year in Pharma Commercial Solutions

Honored for AI-Driven Innovation, Measurable Client Impact, and Industry-Leading Commercialization Excellence BERKELEY HEIGHTS, N.J., March 25, 2026 /PRNewswire/ -- Axtria Inc. ...

2026-03-25 20:33 3583

Waterdrop Q4 and FY2025 Financial Results: Q4 operating revenue rises 105.5% YoY, and declared a cash dividend

BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividen...

2026-03-25 20:24 4981

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the...

2026-03-25 20:00 4338

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics ...

2026-03-25 20:00 5083

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today * The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal ...

2026-03-25 19:00 4245

ENNOVI Secures German Patent Approval for Adhesive-Free Lamination in Battery Cell Contacting Systems

Offering a new, validated CCS design pathway, reducing uncertainty for cautious battery engineers NECKARSULM, Germany, March 25, 2026 /PRNewswire/ -- ENNOVI

2026-03-25 19:00 4368

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...

2026-03-25 18:22 5721

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...

2026-03-25 18:00 4361

VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial

* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...

2026-03-25 17:11 3685

Why Chronic Eczema Can Last for Decades, and What a Recent Case Is Revealing

Tangs Clinical TCM Highlights Why Chronic Eczema Can Persist for Decades SINGAPORE, March 25, 2026 /PRNewswire/ -- A recent patient case managed by Tangs Clinical TCM has shed light on why chronic eczema can last for years, and how long-term, structured management may influence symptom patterns o...

2026-03-25 15:40 2381

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results f...

2026-03-25 14:32 4126
1 ... 20212223242526 ... 649